With more than 60 years of expertise, HAL Allergy (NL) is a privately owned, European specialty biopharma company dedicated to allergies and related diseases. Its foundation rests on proprietary allergen extraction, advanced allergoid technology, and GMP-certified manufacturing. On this basis, the company covers the full allergy care pathway – from diagnostics and allergen immunotherapy through to next-generation treatments. Supported by continued investment in R&D and a robust clinical pipeline, HAL Allergy aims to expand beyond allergy into adjacent disease areas, leveraging its expertise to transform the lives of a broad population of patients. Join HAL Allergy and drive innovation!
Looking for a particular HAL Allergy Group employee's phone or email?
The HAL Allergy Group annual revenue was $61.1 million in 2026.
Pieter Flore is the CEO of HAL Allergy Group.
199 people are employed at HAL Allergy Group.
The NAICS codes for HAL Allergy Group are [32541, 3254, 32, 325].
The SIC codes for HAL Allergy Group are [283, 28].